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Title: Corrections of Research Report: Descriptive Study of Surrogate and Clinical 
Outcomes of Antiretroviral treatment in Selebi Phikwe, Botswana from June 2004 to June 
2005 
Key: Changes are reflected in bold. 
Presentation:  
1) Grammar and spellings: A robust spelling and grammar editing has been done. However, 
there could still a few grammar and spelling mistakes that escaped the eye 
2) The investigator team is referred in third person  
3) Each Chapter is introduced  
Literature Review 
1) Role of Trials in the evolution of ART has been stated on page 4: 
1.4.1 Trials aimed at safety and efficacy of anti HIV drugs: The observation of the 
first cases of the newly acquired immunodeficiency syndrome (AIDS) back in 1981 
subsequently led to an unfortunate spread of the disease and a rising death toll. 
Along with the sharp rise in HIV-related morbidity and mortality, public awareness 
of urgent need for effective antiretroviral (ARV) therapy rose (Emmelkemp and 
Rockstroh, 2007). Phase II clinical trials were to play an important role in helping to 
understand the efficacy and safety of the early ARV drugs. In 1987, a double-blind 
placebo-controlled trial including 282 patients with AIDS was performed. The 
efficacy of oral AZT 250mg every four hours was evaluated and compared with 
placebo. After 24 weeks, treatment with AZT was associated with lower occurrence 
of opportunistic infections, significantly lower mortality, and a higher increase in 
CD4 count compared with placebo (Emmelkemp and Rockstroh, 2007). However, 
there are numerous dissident views that phase II trials for early ARV drugs may 
have been rushed because of the urgency to stem the AIDS mortality.  
 
2) More information on Monotherapy has been included on page 4: 
1.4.2 Monotherapy: The first ARV substance to become available was Zudovudine 
(AZT) (Emmelkemp and Rockstroh, 2007) and the first available agents to treat HIV 
infection were nucleoside reverse transcriptase inhibitors such as Zidovudine (AZT), 
lamivudine (3TC), and didanosine (ddl) (Youle and Wainberg, 2003). However, after 
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initial promising results of short-course treatment with first nucleoside reverse 
transcriptase inhibitors (NRTIs), disappointment was great when studies with 
longer follow-up showed no superiority in disease progression and survival 
(Emmelkemp and Rockstroh, 2007). The Concorde study in 1994 showed that after 
a median follow-up of 3.3 years there was no statically significant difference in 
clinical outcome between patients treated immediately at randomization with AZT 
250mg every four hours and those receiving placebo or deferred ARV treatment in 
case of advanced disease. Several trials further indicated that early initiation on 
AZT monotherapy in asymptotic HIV-infected patients was not beneficial 
(Emmelkamp and Rockstroh, 2007). 
 
3) More information has been included on how HAART came about on page 5 
4.13 Combination therapy/Highly Active Antiretroviral Therapy (HAART): 
Because the benefits of monotherapy with AZT had been shown to be only transient 
or insignificant, there was strong need for the development of new ARV therapy and 
strategies. In this context, new trials were initiated to evaluate the efficacy of ARV 
combination therapy.  In 1995, the Delta trial compared AZT monotherapy with a 
combination of AZT with didanosine (ddl) or Zalcitabine (ddl). This large 
international trial included 3,207 patients and reported a significant difference in 
survival between the treatment groups (Emmelkemp and Rockstroh, 2007). A 
Glaxo-Wellcome sponsored study has demonstrated that the addition of lamivudine 
(3TC) to ATZ monotherapy improved clinical outcomes, at least in the short term 
(Gazzard, 2001).  Further studies have demonstrated that protease inhibitors contained in 
triple therapy combinations delayed clinical events, as compared with dual nucleoside 
regimes (AZT/3TC), in a group of patients with advanced disease who had at least three 
months of previous AZT monotherapy experience.  A systematic review, meta analysis 
and meta-regression of 54 fully reported randomized trials has also shown that triple 
therapy has significantly improved clinical and surrogate outcomes compared with dual 
therapy (Jordan, Gold, Cummins and Hyde, 2003).  Since the major biological factor in 
failure of antiretroviral therapy is the development of viral mutations which confer 
resistance to specific antiretroviral agents, a two drug regimen has a more durable effect 
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than a single drug regimen, simply because more viral mutations are required to confer 
resistance to two antiretroviral drugs. Similarly, resistance to a potent three drug regimen 
generally takes longer to develop than to a two drug regimen (Carpenter, 2002). 
 
4) Provisos for a successful ART program are included on page 6 
1.4.5 Provisos for a successful ART program: The provisos for a successful ART 
program differ from those of other disease programs in a lot of ways because 1) 
most ART treatment programs usually have a backlog of patients in immediate need 
of treatment at the same time, 2) despite having the highest burden of HIV, sub-
Saharan Africa does not have adequate numbers of HIV practitioners to treat HIV-
infected patients, and 3) infrastructure and equipment required for treating HIV is 
often inadequate. A good HIV program should provide standardized and affordable 
and/or free HIV treatment, standardized monitoring systems, uninterrupted drug 
supply, decentralized ART clinics to improve physical access, community 
involvement, and use of ART services to deliver other services such as family 
planning. In a review of ART programs conducted by Akileswaran and others, the 
program that accounted for the highest mortality rate of 27% required its patients 
to pay for medication, and other authors admitted that safety and efficacy became 
compromised as a result (Akileswaran, 2005). Stringer and others (2006) report that 
the Zambian ART program scored early successes because of leadership and 
advocacy by the Zambian government, task-shifting to address physician shortage, 
funding from PEPFAR and the Global Fund, and a sound information system. 
 
5) Definitions of outcomes are included on page 8 
1.4.9 Outcomes (Definition): Treatment outcomes reported from various clinics in sub-
Saharan Africa, Haiti, Asia and South America have been good, comparable with those 
observed in countries with higher incomes.  Patient outcomes are usually categorized as 
patients alive and on treatment, stopped treatment, transferred to another facility, dead or 
“lost to follow-up” (Joseph Kwong-Leung Yu, et al.,2007).   A South African study 
conducted at the Ndlovu Medical Center (NMC) categorized outcomes as 1) patient 
retention (proportion of patients remaining in care, combined with the proportion 
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of patients who had been transferred to other clinics, 2) patient attrition (all-cause 
mortality plus loss to follow-up), 3) Virological suppression (achieving HIV-RNA 
below 50 copies/ml, and 4) immunological failure (failure to raise CD4 counts to 
more than 100 cells/ml (Barth, 2011). 
 
6) Clinical outcomes strengthened on page 8 
1.4.10 Clinical Outcomes: Clinical outcomes for patients on ART in resource-limited 
countries are comparable to those of the first world.  A search of academic 
databases and recent conference abstracts involving studies from 14 countries 
reported improved clinical outcomes in all the studies in terms of weight gain and 
reduced mortality (median mortality was 7%) (Akileswaran, 2005). However, 
methodological discrepancies between the African studies and those coming out of 
industrialized may also account for the inability to easily compare data. In a report 
by Stringer and others (2006) on the outcomes of 16,000 patients receiving ART 
from 18 public sector health facilities in Zambia between April 2004 and November 
2005, a total of 1,142 (7%) patients receiving ART died and death occurred within 
the first 90 days on treatment; after 90 days, there were only 5 deaths per 100 
patient-years, comparable to the rates in the first world; and 861 patients failed 
therapy (therapy failure defined as worsening stage of disease after three months of 
therapy or return of CD4 below pre-treatment levels. A retrospective analysis of a 
cohort of adults who initiated on treatment in five public sector sites in three 
African countries reported a mortality rate of 8 deaths per 100 person-years and 
mortality was highest in the thirst six months of treatment (Palombi, L., et al, 2008).  
 
7) Additions to Laboratory outcomes on page 9 
1.4.11 Laboratory Outcomes: A recent clinical trial on the effects of the current 
generation of ART drugs on viral loads has demonstrated a viral suppression to <50/ml in 
70% of subjects (Havlir, 2004).  Miller (2004) also observes that the current therapy for 
HIV-1 can achieve full suppression of HIV-1 RNA (<50 copies/ml).  However, achieving 
a higher level of viral suppression does not always confer greater increase in CD4 counts, 
much against previous studies (Havlir, 2004).  Another study which reviewed twenty-
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eight abstracts and articles involving 14 African countries on the feasibility of 
implementation of ART programs and clinical and laboratory outcomes has demonstrated 
an increase in the mean and median CD4 count, a median of 73% patients with 
undetectable viral loads, median weight gain of 5.0kg, and median mortality rate of 7.4% 
using a regimen of two nucleoside reverse transcriptase inhibitors (NRTI) and one non 
nucleoside reverse transcriptase inhibitor (NNRTI) (Akileswaran, et al., 2005).  A 5.4 
month follow-up of 709 on the national public ART program in Botswana to determine 
clinical and laboratory outcomes on ART showed that patients managed in a national 
ARV program in resource poor areas have clinical outcomes comparable with those in 
well-resourced areas even when they start treatment at relatively low CD4 counts 
(Naledi, N.T., et al., 2004).  The weaknesses of this study that would limit its use in 
predicting ART outcomes of other national ARV programs in similar settings are the 
short period of follow-up and the relatively small numbers of experimental subjects.  In 
South Africa, a follow-up of 287 treatment naïve adult patients in a community-based 
antiretroviral therapy (ART) program established in 2001 in a South African township 
has also demonstrated that ART can be provided in resource-limited settings with good 
patient retention and clinical outcomes(Coetzee, et al, 2004).  The weakness of this study 
limiting its use in predicting outcomes in similar settings is the small number of 
experimental subjects. The South African study conducted at the Ndlovu Medical 
Center including 735 adults who started ART showed the following outcomes: 1) 
retention rate was 65%, 2) mortality was the main cause of attrition, 3) mortality 
typically occurred in the first three months of initiation of treatment, 4) viral 
repression in 76% of the patients, and 13% immunological failure (Barth, et al., 
2011) 
 
8) Additions to adherence on 10 Page: 
1.4.12 Adherence: Although there is no universally accepted definition of adherence, 
medication adherence may be defined as the extent to which a patient takes a medication 
in the way intended by a health care provider (Machtinger and Bangsberg, 2006).  
Antiretroviral adherence is the second strongest predictor of progression to AIDS and 
death, after CD4 count (Machtinger and Bangsberg, 2006).  Patients therefore need to 
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adhere to treatment to ensure good clinical and laboratory outcomes. Adherence to ART 
is most impactful if it is observed from the beginning of treatment. Research has 
demonstrated that the initial response to ART has long-term prognostic significance, and 
optimizing adherence in early months is important for ensuring long-term immunological 
and virological success (Brinkholf, W. G., et al., 2009).  Data on when (phase during 
treatment) non-adherence is most likely to occur in an ART program is mixed.  Data from 
the ART-LINC collaboration and other treatment programs such as the Médecins Sans 
Frontières (MSF) program in Malawi show that loss to follow-up and death mostly occur 
in the first 6 months after ART initiation (Brinkholf, W. G., et al., 2009).  Not all studies 
confirm this, however.  Data from a South African ART programs demonstrate that while 
mortality decreased rapidly after ART initiation, the rate of loss to follow-up remained 
fairly constant during the first 2 years (Brinkholf, W. G., et al., 2009).     
 
The level of adherence has significant impacts on clinical and laboratory outcomes for 
individuals taking ART.  Studies have demonstrated that ART requires an adherence rate 
of more than 95% for good virologic and immunological response (ARV Project 
Description Document, Government of Botswana, 2002).  Adherence to ART of more 
than 95% has been shown to suppress viral loads to less 400 copies/ml in 78% of 
patients; 90-95% adherence has resulted into similar viral decay in only 45% of patients;  
80-90% adherence has suppressed viral loads in 33% of patients; 70-80% adherence has 
been shown to suppress viruses in only 29% of patients; and less than 70% adherence 
suppresses viruses in only 18% of patients (Bartlett and Gallant, 2004).  A randomized 
controlled trial conducted between 1996 and 1998 to determine the association between 
adherence and virological response, has shown that patients exhibiting biological success 
had significantly greater adherence early in therapy compared with patients who failed, 
and that greater adherence was required for viral decay to less than 50 copies/ml than for 
400 copies/ml (Rathbun and Farmer, 2002. 
 
The performance of various ART programs in the area of adherence has been fairly 
mixed.  Using data on the performance of different ART programs in resource-limited 
settings in relation to adherence, Brinkhof
 
and others (2009) have found out that 21% of 
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patients had been lost to follow-up by 15 programs within the first six months.  Another 
study in an urban primary health care setting of Kamapala, Uganda, 3406 (21%) of 16 
199 patients starting ART in 2004–2005 were more than 30 days late for a scheduled 
pharmacy appointment (Brinkholf, W. G., et al., 2009). A South African study at the 
Ndlovu Medical Center had an attrition rate of 35% (comprising actual loss to 
follow-up and patients who died while on treatment (Barth, 2011). 
In a prospective study, 140 individuals in a public hospital HIV clinic were followed for 
one year after initiation of ART.  The investigators assessed adherence using three 
methods: a computer chip embedded in a specially designed pill-bottle cap to record the 
time and duration of each bottle opening (microelectronic monitoring system (MEMS), or 
MEMS caps), pill count, and self-report.  They calculated a composite adherence rate 
including all three measures that demonstrated a mean adherence rate of 71% 
(Machtinger and Bangsberg, 2006).  
 
Studies show that loss to follow-up is mainly due to the large number of patients that 
programs have to follow-up in public programs.  Brinkhof
 
and others (2009) observe that 
treating the maximum number of new patients possible has been the top priority for many 
public sector programs, with the possible consequence that documenting and tracing 
patients lost to follow-up has become increasingly inadequate.  Using data from a large 
collaborative network of ART treatment programs in resource-limited settings, Brinkhof
 
and others (2009) also found out that the percentage of patients lost to programs was 
substantially greater in more recent calendar periods than in the period before the year 
2000.  This suggests that many sites find it increasingly difficult to follow-up the growing 
population of patients and to trace those not returning to the clinic ((Brinkholf, W.G., et 
al., 2009).  Other documented reasons for loss to follow-up are drug abuse, low 
household economies, and old age.  A study conducted to explain reasons for missed 
appointments has concluded that substance abuse is a leading cause of poor adherence 
and eventual loss to follow-up (Hewitt, et al., 2002).  Oyugi and Bangsburg (2002) have 
also argued through studies that household economies have an impact on the levels of 
adherence. Low household income limits access to health services, including ART 
services because the little income will be deviated to food and other needs and not 
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health. In the Botswana program, adherence by individual patient’s frequency of 
attended medical refill, while loss to follow-up was patients who could be traced for 
at least three months (Bussmann, 2008). 
 
Chapter 2: Introduction to Methods and Materials 
 
1) Introduction to Chapter 2 is inserted on page 12 
2.1 Introduction to Methods and Materials 
This chapter describes the 1) study design, 2) study site and reasons for its selection, 
3) study population, 4) sampling methods, 5) sources and methods of capturing, 
cleaning, and analyzing data, 7) quality of data, and 8) ethical considerations during 
the entire process 
2) Sub-points 2.4 and 2.5 are merged in 2.3 on page on page 13 
3) Population size included on page 15 
2.3.9 Sampling not required; all patients enrolled on ART during this period were 
included 
Sampling was not required for this study because it was apparent during the study design 
that the population of HIV-infected patients initiated on therapy would not be too large to 
require a representative sample to be drawn from the study population. It was feasible 
that all the patients screened for ART and started on ART would be included in the study. 
The population was 904 adults started on ART  
4) Information on data processing, including coding included on page 18 
2.9 Data Processing 
Data was imported onto an electronic excel spreadsheet for descriptive statistical 
analysis. For numerical data such as age (which were already represented by 
numbers), those numbers were used as codes. For non numerical variables such as 
gender/sex, codes were created for male and female. This was done during the 
extraction of data.   
 
5) All the tables have been redone to include percentages from pages 22-28 
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Table 1: HIV-infected adult patients started on ART 
   
Age range 
Number of patients started 
on ART Percentage by age range 
15-19 17 1.80% 
20-24 38 4.20% 
25-29 151 17% 
30-34 177 20% 
35-39 161 18% 
40-44 145 16% 
45-49 83 9% 
50-54 80 9% 
55-59 50 5% 
60-64 2 0% 
65-70 0 0.00% 
 Total 904 100.00% 
 
 
Table 2: Number of patients started on ART disaggregated by age and sex 
 
Age 
range 
Female
s Males Total 
% of 
females % of males 
15-19 9 8 17 53% 47% 
20-24 23 15 38 61% 39% 
25-29 108 43 151 72% 28% 
30-34 121 56 177 68% 32% 
35-39 92 69 161 57% 43% 
40-44 87 58 145 60% 40% 
45-49 47 36 83 57% 43% 
50-54 42 38 80 53% 48% 
55-59 19 31 50 38% 62% 
60-64 1 1 2 50% 50% 
65-70 0 0 0 0 0 
Total 549 355 904 61% 39% 
 
 
3.3 Basal CD4 counts for adult patients started on ART 
Most adult patients started on ART in selebi Phikwe, Botswana had a relatively low CD4 cellular 
count.  The lowest count recorded was 1 cell per milliliter of blood. The mean count was 54 cells 
per milliliter of blood.  The median count was 25 cells per milliliter of blood.   
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Table 3: Frequency table showing basal CD4 range for patients initiated on ART 
 
 
CD4 range females Males Total % of patients per CD4 
band 
> 10 227 161 388 43% 
ten -25 33 22 55 6% 
26-50 65 54 119 13% 
51-100 113 68 181 20% 
101-200 66 43 109 12% 
201-300 32 7 39 4% 
Unknown 13 0 13 1% 
Total 549 355 904 100% 
     
 
 
 
3.4 CD4 counts after 12 months of treatment 
After 12 months of treatment with ART, there was no patient with a CD4 cellular count of less 
than 50 cells per milliliter of blood. The mean CD4 count rose to 181 and the median to 147 cells 
per milliliter of blood.    
Table 4: Frequency table shows the distribution of CD4 counts in adult patients initiated on ART 
after 12 months of treatment. 
 
CD4 range at 12 months of ART Females Males Total 
< 10 0(0%) 0(0%) 0 (0%) 
10 25 0(0%) 0 (0%) 0 (0%) 
25-50 0(0%) 0 (0%) 0 (0%) 
50-100 15(2%) 8 (1%) 23 (29%) 
100-200 230(28%) 157 (20%) 387 
(48%) 
200-300 124(15%) 76 (9%) 200 
(24%) 
300-400 48(6%) 51 (6%) 99 (12%) 
400-500 32(4%) 7 (1%0 39 (5%) 
500-600 20(3%) 9 (1%) 29 (4%) 
600-700 13(2%) 3 (0%) 16 (2%) 
700-800 11(1%) 0 (0%) 11 (1%) 
Total 493(61%) 311 (39%) 804 
(100%) 
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3.5 Mortality while on ART  
Of the 904 adult patients started on ART, 84 patients (43 females and 41 males) died within 12 
months of commencement of ART. 
 
Table 5: Frequency table showing mortality outcome while on ART 
 
Age range for patients who died female Male Total 
15-19 1 (1%) 0 (0%) 1 (1%) 
20-24 1 (1%) 0 (0%) 1 (1%) 
25-29 10 (12%) 5 (6%)  15 (18%) 
30-34 8 (10%) 6 (7%) 14 (17%) 
35-39 6 (7%) 10 (12%) 16 (19%) 
40-44 5 (6%) 6 (7%) 11 (13%) 
45-49 6 (7%) 7 (8%) 13 (15%) 
50-54 4 (5%) 4 (5%) 8 (10%) 
55-59 2 (2%) 3 (4%) 5 (6%) 
60-64 0 (0%) 0 (0%) 0 (0%) 
65-70 0 (0%) 0 (0%) 0 (0%) 
 
 
 
 
3.6 Proportion of female who died while on ART 
      Forty three female patients (8%) died while on ART. 
 
 
Table 6: Proportion of mortality among females 
 
Total number adult females initiated on 
ART 
549 
Total Number of females who died while 
ART 
43 
Proportion of females who died while on 
ART 
8% 
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3.7 Proportion of males who died while on treatment 
Forty one male patients (12%) died while on treatment 
 
Table 7: Proportion of mortality among males 
 
Total number adult males initiated on ART 355 
Total Number of males who died while 
ART 
41 
Proportion of males who died while on 
ART 
12% 
 
3.8 Time on treatment before death 
Of the 84 patients who died while on treatment, close to 60% of them died in the first three 
months of commencement of treatment. 
 
Table 8: Length on treatment before death 
 
  Female Males Total 
        
< 1 month 15 (18%) 12 (14%) 27 (32%) 
1-2 months 5 (6%) 6 (7%) 11 (13%) 
2-3 months 6 (7%) 4 (5%) 10 (12%) 
3-4 months 3 (3%) 3 (3%) 6 (6%)  
4-5 months 3 (3%) 0 (0%) 3 (3%) 
5-6 months 2(3%) 2 (3%) 4 (6%) 
6-7 months 2 (3%) 2 (3%) 4 (6%) 
7-8 months 1 (1%) 1 (1%) 2 (2%) 
8-9 months 2 (3%) 6 (7%) 8 (10%) 
9-10 months 1 (1%) 0 (0%) 1 (1%) 
10-11 months 0 (0%) 3 (3%) 3 (3%) 
11-12 months 3 (3%) 2 (3%) 5(6%) 
Total 43 (51%) 41 (49%) 84 
(100%) 
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3.9 Basal CD4 counts for patients who died 
Mortality was higher among patients with low basal CD4 counts. Of the 84 patients who died 
while on treatment, 75 of them had a CD4 cellular count of less than 10 cells per milliliter of 
blood. 
 
 
Table 9: Frequency table showing the basal CD4 counts for patients who died  
 
 
Basal CD4 count for adult patients who died Female Male Total 
< 10 39 (47%) 36 (43%) 75 (89%) 
10 25 1 (1%) 2 (2%) 3 (4%) 
25-50 1 (1%) 3 (4%) 4 (5%) 
50-100 2 (2%) 0 (0%) 2 (2%) 
100-200 0 (0%0 0 (0%) 0 (0%) 
200-300 0 (0%) 0 (0%) 0 (0%) 
300-400 0 (0%) 0 (0%) 0 (0%) 
400-500 0 (0%) 0 (0%) 0 (0%) 
 Total 43 (51%) 41 (49%) 84 (100%) 
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Table 10: Frequency table of Age range of patients who died 
 
 
Age range for patients who died female Male Total 
15-19 
1 
(1%) 0 (0%) 1 (1%) 
20-24 
1 
(1%) 0 (0%) 1 (1%) 
25-29 
10 
(12%) 5 (6%)  15 (18%) 
30-34 
8 
(10%) 6 (7%) 14 (17%) 
35-39 
6 
(7%) 10 (12%) 16 (19%) 
40-44 
5 
(6%) 6 (7%) 11 (13%) 
45-49 
6 
(7%) 7 (8%) 13 (15%) 
50-54 
4 
(5%) 4 (5%) 8 (10%) 
55-59 
2 
(2%) 3 (4%) 5 (6%) 
60-64 
0 
(0%) 0 (0%) 0 (0%) 
65-70 
0 
(0%) 0 (0%) 0 (0%) 
 Total 
43 
(51%) 41 (49%) 84 100%) 
 
 
 
3.10 Lost to follow-up 
Of the 904 patients started on treatment, 16 (2%) were lost to follow-up 
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Table 11: Frequency table of age range of patients lost to follow-up 
 
 
Age range for patients lost to follow-up Females Males Total 
< 20 years 0 (0%) 1 (6%) 1 (6%) 
20-25 years 1 (6%) 1 (6%) 2 (13%) 
26-30 years 2 (13%) 2 (13%) 4 (25%) 
31-35 years 1 (6%) 1 (6%) 3 (19%) 
36-40 years 3 (19%) 3 (19%) 5 (31%) 
41-45 years 1 (6%) 0 (0%) 1 (6%) 
Total 8 (50%) 8 (50%) 16 (100%) 
 
 
Discussion 
1) Proportion of individuals put on ART against target is described on page 29 
4.2 Total Number of Patients Started on ART by Age Range: In all, 904 adult patients 
were initiated on ART in Selebi Phikwe, Botswana from June 2004 to June 2005. The 
number of adult patients started on ART was relatively small (15%) compared to 
the estimated number of patients (6,000) in need of ART. The main reason for this 
low enrollment was the limited capacity of the health system to enroll all the ART 
eligible adult patients. New ART programs in sub-Saharan Africa where the burden 
of HIV is high have issues of patient carrying capacity. 
2) Effects of HIV on productive age group described on page 29 
4.3 Age Range Most in Need of ART: Of the 904 adult patients initiated on ART during 
the study period, 689 (representing 76%) were between the ages of 15-49.  This finding is 
consistent with several studies that have shown that the bulk of people with HIV 
infections are likely to consist of people between the ages of 15-49.  Homas Goliber 
(2010) observes from various studies that both HIV and AIDS strike hardest among 
people 15 to 49 years. The high burden of HIV among the economically active sub-
population has socio-economic consequences on the district and the country. The 
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burden increases medical absenteeism, increases the cost of doing business through 
new recruitments to replace sick workers and medical bills, and increases the 
dependency ratio. Additionally this same age group is needed for delivery of health 
services, including ART. Therefore, this affects the rate of expansion of ART 
services. 
Chapter 5 
1. Conclusion added on page 34 
5.1 Conclusion 
This study shows that it is feasible to implement a public sector ART program 
providing free ART services for free in resource-limited settings such as sub-
Saharan Africa. The study also confirms that such programs could have similar 
outcomes to those programs implemented in the developed world. 
 
 
 
 
